DigestRedComo funciona
Red
/
Empresas
Au
No verificado

Autobahn Therapeutics

Sobre qué escribimos

BiotecnologíaEventosFarmacéuticaMedicina - VariosSalud

12 Comunicados de prensa

Ver todos los comunicados de prensa
16/01/2026
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
Eventos
Industria
Autobahn Therapeutics Presents New Preclinical Data at ACNP Annual Meeting Supporting Novel Restorative Neuroplasticity Mechanism of Elunetirom
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
17/12/2025
Eventos
Psiquiatría
Salud
Sanidad
Farmacéutica
Biotecnología
Autobahn Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
10/11/2025
Biotecnología
Psiquiatría
Salud
Farmacéutica
Eventos
Autobahn Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
08/07/2025
Psiquiatría
Salud
Ciencia
Farmacéutica
Biotecnología
Eventos
Autobahn Therapeutics to Participate in Evercore’s Emerging Private Biotech Conference
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
27/05/2025
Eventos
Biotecnología
Psiquiatría
Salud
Farmacéutica
Autobahn Therapeutics to Participate in Jefferies Global Healthcare Conference
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
23/05/2025
Eventos
Industria
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
08/01/2025
Industria
Biotecnología
Psiquiatría
Salud
Farmacéutica
Medicina - Varios
Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
12/11/2024
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Eventos
Finanzas
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
22/10/2024
Industria
Psiquiatría
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
Autobahn Therapeutics Announces FDA Clearance of IND Application for ABX-002 as an Adjunctive Treatment for Bipolar Depression
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
16/09/2024
Industria
Biotecnología
Psiquiatría
Salud
Farmacéutica
Medicina - Varios
Autobahn Therapeutics Announces Initiation of its AMPLIFY Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Major Depressive Disorder
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0